PDS Biotechnology Announces Conference Call and Webcast for First Quarter Financial Results
April 26 2021 - 4:15PM
PDS Biotechnology Corporation (Nasdaq: PDSB), a clinical-stage
immunotherapy company developing novel cancer therapies and
infectious disease vaccines based on the Company’s proprietary
Versamune® T-cell activating technology, today announced that the
Company will release financial results for the first quarter of
2021 on Thursday, May 13, 2021, before the market opens. Following
the release, management will host a conference call to review the
financial results and provide a business update.
The conference call is scheduled to begin at 8:00
am ET on Thursday, May 13, 2021. Participants should dial
877-407-3088 (United States) or 201-389-0927 (International) and
mention PDS Biotechnology. A live webcast of the conference call
will also be available on the investor relations page of the
Company's corporate website at www.pdsbiotech.com.
After the live webcast, the event will be archived
on PDS Biotech’s website for 6 months. In addition, a telephonic
replay of the call will be available for 6 months. The replay can
be accessed by dialing 877-660-6853 (United States) or 201-612-7415
(International) with confirmation code 13718826.
About PDS BiotechnologyPDS Biotech
is a clinical-stage immunotherapy company with a growing pipeline
of cancer immunotherapies and infectious disease vaccines based on
the Company’s proprietary Versamune® T-cell activating technology
platform. Versamune® effectively delivers disease-specific antigens
for in vivo uptake and processing, while also activating the
critical type 1 interferon immunological pathway, resulting in
production of potent disease-specific killer T-cells as well as
neutralizing antibodies. PDS Biotech has engineered multiple
therapies, based on combinations of Versamune® and disease-specific
antigens, designed to train the immune system to better recognize
disease cells and effectively attack and destroy them. To learn
more, please visit www.pdsbiotech.com or follow us on Twitter at
@PDSBiotech.
Media & Investor Relations Contact:
Deanne Randolph
PDS Biotech
Phone: +1 (908) 517-3613
Email: drandolph@pdsbiotech.com
Rich Cockrell
CG Capital
Phone: +1 (404) 736-3838
Email: pdsb@cg.capital
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Mar 2024 to Apr 2024
PDS Biotechnology (NASDAQ:PDSB)
Historical Stock Chart
From Apr 2023 to Apr 2024